Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Intravascular Large B-Cell Lymphoma Incidence Evaluated
Leuk Lymphoma; ePub 2017 Feb 9; Rajyaguru, et al
The incidence of intravascular large B-cell lymphoma (IVLBCL) increased significantly between 2000 and 2013, according to a population-based study involving 344 individuals.
Investigators looked at incidence, demographic and clinical characteristics, prognostic factors, and survival in participants with IVLBCL, vs those with diffuse large B-cell lymphoma not otherwise specified (NOS). Among the results:
- Age-adjusted incidence IVLBCL rate was 0.095 (case/1 million).
- The incidence increased nearly 10% over the study period.
- The median age at IVLBCL diagnosis was 70 years.
- Median 1-year overall survival rate was 66%; the median 2- and 3-year rates were 52% and 46%, respectively.
- The 5-year overall survival of IVLBCL and DLBCL NOS were similar—~46% in both groups.
- Advanced age, advanced stage, and having Medicaid or Medicare insurance predicted worse overall survival in IVLBCL.
- Female gender and use of radiation therapy predicted better survival.
Rajyaguru D, Bhaskar C, Borgert A, Smith A, Parsons, B. Intravascular large B-cell lymphoma in the United States (US): A population-based study using Surveillance, Epidemiology, and End Results program and National Cancer Database. [Published online ahead of print February 9, 2017]. Leuk Lymphoma. doi:10.1080/10428194.2017.1287363.